The treatment for mTNBC is evolving with the identification of biomarkers and clinical trials revealing new treatment options. Join us to hear from our expert guests, Dr. Paolo Tarantino, an advanced research fellow at Dana-Farber Cancer Institute and at Harvard Medical School, and Dr. Ana Garrido-Castro, Breast Medical Oncologist at Dana-Farber Cancer Institute (DFCI) and Assistant Professor of Medicine at Harvard Medical School.They will present the important changes in genetic/ biomarker diagnostics, immunotherapy as well as emerging therapies. This presentation will also highlight racial disparities and how TNBC disproportionately affects the Black community. Register now and discover your clinical options. Feel free to bring any questions you may have for discussion after the presentation.
Key Takeaways from Webinar Viewers:
- “The presentation was clear to understand the basic breakdown for administering mTNBC treatments such as PD-L1 and BRCA status and lines of treatment as well as potential clinical trials.”
- “I have a better understanding of how anti-body-drug combinations work.”
- “Clinical trials are a way to be able to receive newer treatments.”